Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Deferred income | (1,826) | (1,795) |
| Net cash used in operating activities | (37,996) | (23,050) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (71) | (64) |
| Purchases of marketable securities | (60,598) | (29,926) |
| Proceeds from sales and maturities of marketable securities | 40,000 | 54,989 |
| Payments of deferred transaction consideration for in-licensed assets | — | (833) |
| Net cash (used in) provided by investing activities | (20,669) | 24,166 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's capex?
- Aclaris Therapeutics (ACRS) reported capex of $58K in Q2 2026.
- How has Aclaris Therapeutics's capex changed year-over-year?
- Aclaris Therapeutics's capex increased by 176.2% year-over-year, from $21K to $58K.
- What is the long-term trend for Aclaris Therapeutics's capex?
- Over 2 years (2022 to 2025), Aclaris Therapeutics's capex has grown at a -57.2% compound annual growth rate (CAGR), from $605K to $111K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Aclaris Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude